The Myeloma Beacon http://www.myelomabeacon.com Independent multiple myeloma news, resources, and online forums for patients, caregivers, and others interested in multiple myeloma. Wed, 08 Feb 2012 19:21:37 +0000 http://backend.userland.com/rss092 en Perifosine Combination May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011) The final results of a Phase 1/2 clinical trial indicate that perifosine in combi­nation with Velcade and dexamethasone may be effective in mul­ti­ple myeloma patients who previously relapsed from or were treatment-resistant to Velcade.

Dr. Philip McCarthy from the Roswell…

]]> http://www.myelomabeacon.com/news/2012/02/08/perifosine-combination-may-be-effective-in-relapsed-refractory-multiple-myeloma-ash-2011/ Sean’s Burgundy Thread: Just This Week Just this week, an acquaintance of mine passed away due to complications from his long-running battle against multiple myeloma.  He was treated at the same out-of-state myeloma clinic at which I was treated. We occasionally ran into each other at…

]]> http://www.myelomabeacon.com/headline/2012/02/07/seans-burgundy-thread-just-this-week/ Beacon NewsFlashes – February 6, 2012 Viracept Demonstrates Anti-Myeloma Activity – Results of a recent preclinical trial show that Viracept (nelfinavir), alone or in combination with other common myeloma drugs, prevents myeloma cell growth and causes cell death. Viracept is a protease inhibitor and is…

]]> http://www.myelomabeacon.com/news/2012/02/06/beacon-newsflashes-february-6-2012/ Siltuximab May Be Effective In Certain Patients With Advanced Multiple Myeloma (ASH 2011) The results of a recent Phase 2 clinical trial suggest that siltuximab in combination with dexamethasone may be effective for some multiple myeloma patients resistant to prior dexamethasone-containing treatments. However, siltuximab in combination with high-dose dexamethasone may be associated with…

]]> http://www.myelomabeacon.com/news/2012/02/03/siltuximab-may-be-effective-in-certain-patients-with-advanced-multiple-myeloma-ash-2011/ Pat’s Place: Multiple Myeloma Survivors Need To Take Regular “Myeloma Breaks” Over the past month, I have once again experienced a wide variety of multiple myeloma-related events that I have heard about over the years.

One thing is for sure:  I don’t recover from sicknesses nearly as well as I used to…

]]> http://www.myelomabeacon.com/headline/2012/02/02/pats-place-multiple-myeloma-survivors-need-to-take-regular-myeloma-breaks/ Experts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma A group of myeloma experts from the International Myeloma Working Group recently published a consensus statement on maintenance therapies for myeloma patients.

In their statement, the experts reviewed the main findings from previous clinical trials that investigated the impact of…

]]> http://www.myelomabeacon.com/news/2012/02/01/experts-publish-consensus-statement-on-maintenance-therapy-in-multiple-myeloma/ Birds In Spring: Waiting On Carfilzomib I try to make a point about not talking in my column too much about whatever symptom, side effect, or malady is affecting me at any particular time.

But suffice it to say that lately there has been a lot…

]]> http://www.myelomabeacon.com/headline/2012/01/31/birds-in-spring-waiting-on-carfilzomib/ Big Sis In Burgundy: R Is For Remission First, I must thank all of you for your interest in my first column, “My Sister Has What?!?!?”  I was surprised and humbled to receive the news that it was one of the Beacon’s top columns for 2011.

However,…

]]> http://www.myelomabeacon.com/headline/2012/01/30/big-sis-in-burgundy-r-is-for-remission/ The Top Myeloma Beacon Patient And Caregiver Columns Of 2011 Over the course of 2011, multiple myeloma patients and caregivers graciously shared their personal experiences with myeloma in columns they wrote for The Beacon.

Some have taken a chronological approach to describing the events leading up to their diagnosis, through…

]]> http://www.myelomabeacon.com/headline/2012/01/27/top-myeloma-beacon-patient-and-caregiver-columns-of-2011/ Celgene Updates Timeline For Pomalidomide Approval In The U.S. And Europe Celgene announced this morning that it plans to submit an application for the approval of pomalidomide for relapsed and refractory multiple myeloma to the U.S. Food and Drug Administration (FDA) during the first quarter of 2012.

In addition, the company said…

]]> http://www.myelomabeacon.com/news/2012/01/26/celgene-updates-timeline-for-pomalidomide-approval-fda-ema/